News

Zacks Investment Research on MSN1d
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
AstraZeneca AZN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) rendered ...
BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use
BeiGene's Tevimbra gets a highly sought after recommendation.
Zacks Investment Research on MSN2d
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep ...
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III ...
Agence France-Presse1d
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...
Zacks.com on MSN5d
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data ...
Precision Medicine Online1d
EMA's CHMP Recommends Autolus' CAR T-Cell Therapy Aucatzyl for B-ALL
NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...
EU recommends AstraZeneca bladder cancer treatment for approval
EU regulators have recommended AstraZeneca’s Imfinzi for approval in the treatment muscle-invasive bladder cancer (MIBC).
Medscape5d
EMA Recommends Treatment for Maple Syrup Urine Disease
The new infusion for maple syrup urine disease is for patients who cannot have an oral or enteral branched-chain amino ...
Medscape5d
EMA Greenlights Aucatzyl for Adult ALL
The autologous immunotherapy consists of the patient’s own T cells engineered to express a chimeric antigen receptor that ...
Pharmabiz2d
EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer: Basel Monday, May 26, 2025, 12:00 Hrs [IST] Roche an ...
Pharmabiz2d
EMA’s human medicine committee recommends approval of GSK’s Blenrep combinations in relapsed/refractory multiple myeloma
EMA’s human medicine committee recommends approval of GSK’s Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Monday, May 26, 2025, 10:00 Hrs [IST] GSK ...